quarterly return from 2012 vktx

Viking Therapeutics (VKTX) had its best quarter since 2012 in Q1 2024, returning 342.5%.

ASSET	QUARTER	% RETURN
Viking Therapeutics (VKTX)	Q2 2015	-16%
Viking Therapeutics (VKTX)	Q3 2015	-17.24%
Viking Therapeutics (VKTX)	Q4 2015	-41.21%
Viking Therapeutics (VKTX)	Q1 2016	-57.36%
Viking Therapeutics (VKTX)	Q2 2016	-11.27%
Viking Therapeutics (VKTX)	Q3 2016	12.09%
Viking Therapeutics (VKTX)	Q4 2016	-16.2%
Viking Therapeutics (VKTX)	Q1 2017	21.67%
Viking Therapeutics (VKTX)	Q2 2017	-26.53%
Viking Therapeutics (VKTX)	Q3 2017	76.85%
Viking Therapeutics (VKTX)	Q4 2017	101.99%
Viking Therapeutics (VKTX)	Q1 2018	6.85%
Viking Therapeutics (VKTX)	Q2 2018	119.17%
Viking Therapeutics (VKTX)	Q3 2018	83.18%
Viking Therapeutics (VKTX)	Q4 2018	-57.97%
Viking Therapeutics (VKTX)	Q1 2019	34.32%
Viking Therapeutics (VKTX)	Q2 2019	-18.23%
Viking Therapeutics (VKTX)	Q3 2019	-18.1%
Viking Therapeutics (VKTX)	Q4 2019	16.57%
Viking Therapeutics (VKTX)	Q1 2020	-43.27%
Viking Therapeutics (VKTX)	Q2 2020	65.75%
Viking Therapeutics (VKTX)	Q3 2020	-18.72%
Viking Therapeutics (VKTX)	Q4 2020	-3.26%
Viking Therapeutics (VKTX)	Q1 2021	10.96%
Viking Therapeutics (VKTX)	Q2 2021	-5.67%

Related Searches